RGNX vs UNH

Regenxbio faces a significantly elevated risk profile since the last analysis. While its proprietary NAV gene therapy platform and the lead asset RGX-314 (wet AMD) with the AbbVie partnership still offer multi-billion dollar market potential, recent events have introduced substantial uncertainty. The FDA clinical holds on two key pipeline assets (RGX-111 and RGX-121), including a neoplasm case, ra...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...